Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates
Authors:
- 17 June 2011
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 82 (2) , 233-248
Abstract
No abstract availableKeywords
This publication has 116 references indexed in Scilit:
- Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotypeEuropean Journal of Cancer, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialThe Lancet Oncology, 2010
- EPCs and pathological angiogenesis: When good cells go badMicrovascular Research, 2010
- Tumor Self-Seeding by Circulating Cancer CellsCell, 2009
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsThe Lancet Oncology, 2009
- Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patientsLung Cancer, 2008
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889